“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Using combined endpoints to define no evident disease activity (NEDA) is becoming increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS). Historically, NEDA has taken account of the occurrence of relapses, brain magnetic resonance imaging (MRI) lesions and disability worsening, but this approach places emphasis on inflammatory activity in the brain and mostly overlooks ongoing neurodegenerative damage. Combined assessments of NEDA which take account of changes in brain volume or neuropsychological outcomes such as cognitive function may begin to address this imbalance, and such assessments may also consider blood or spinal-fluid neurofilament levels or patient-reported outcomes and quality of life measures. If a combined NEDA assessment can be validated in prospective studies as indicative of long-term disease remission at the individual patient level, treating to achieve NEDA could become the goal of clinical practice and achieving NEDA may become the “new normal” state of disease control for patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Self-citationSiller, N., Kuhle, J., Muthuraman, M., Barro, C., Uphaus, T., Groppa, S., Kappos, L., Zipp, F., & Bittner, S. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518765666 · Cited by 205
Gaetani, L., Höglund, K., Parnetti, L., Pujol-Calderon, F., Becker, B., Eusebi, P., Sarchielli, P., Calabresi, P., Di Filippo, M., Zetterberg, H., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0339-1 · Cited by 178
“Therefore, the assessment of CSF NfL could participate in the future in defining the “ no evidence of disease activity (NEDA) ” status in MS patients, as advocated [39].”
Metadata
- Authors
- Giovannoni, G., Tomic, D., Bright, J. R., & Havrdová, E.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2017-04-06
- Volume
- 23
- Issue
- 9
- Pages
- 1179-1187
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2605302503
- Cited by
- 184
- References
- 1
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. https://app.cochat.ai/papers/10.1177/1352458517703193
- The paper
- Giovannoni, G., Tomic, D., Bright, J. R., & Havrdová, E. (2017). “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458517703193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.